Matrix-MTM, for example, has shown promising results in enhancing antibody responses and CD4+ T cell immunity in the context of NanoFlu—a novel adjuvanted recombinant influenza vaccine currently in late-stage clinical trials [34]. Here, CD4 is linked to influenza.